Cardiovascular implications of HIV-associated dyslipidemic lipodystrophy

Rajagopal V. Sekhar, Farook Jahoor, Henry J. Pownall, Christie M. Ballantyne, Ashok Balasubramanyam

Research output: Contribution to journalReview articlepeer-review

17 Scopus citations


The emergence of a new metabolic syndrome in patients with HIV infection, termed "HIV-associated dyslipidemic lipodystrophy" (HADL), is characterized by central fat redistribution, severe dyslipidemia, and insulin resistance and predisposes to an increased risk of cardiovascular disease. The factors promoting the development of cardiovascular disease in this condition are not well understood and may involve contributions from antiretroviral drugs and components of the HIV virus, as well as inflammatory cytokines, leading to accelerated lipolysis, dyslipidemia, lipotoxic insulin resistance, and vascular inflammation. In this article, we review HADL in terms of metabolic, molecular, and cytokine derangements leading to cardiovascular disease.

Original languageEnglish (US)
Pages (from-to)173-179
Number of pages7
JournalCurrent Atherosclerosis Reports
Issue number3
StatePublished - May 2004

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Cardiovascular implications of HIV-associated dyslipidemic lipodystrophy'. Together they form a unique fingerprint.

Cite this